Aurobindo Pharma Ltd Share Price
As on 05 December 2025 at 15:19 IST
Aurobindo Pharma Q1 FY26 Results:
Net profit after tax fell 10% to ₹825 crores in Q1 FY26, from ₹919 crores in Q1 FY25. Total income for the quarter increased 2.4% year-on-year to ₹7,973 crores, from ₹7,788 crores.
About Aurobindo Pharma Ltd
Aurobindo Pharma Limited is a major Indian pharmaceutical company. It has established itself as a key player in the global healthcare industry since its inception in 1986. The company's headquarters are in HITEC City, Hyderabad. Its extensive product portfolio includes antibiotics, antiretrovirals, cardiovascular products and anti-diabetics. Aurobindo Pharma has established a strong global presence, with its products being sold in over countless countries. This international reach has positioned the company as one of India's largest pharmaceutical firms. The Reddy family maintains a substantial promoter shareholding, providing strong backing for its operations. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
6.44%
Over 6 Months
7.41%
Over 1 Year
-2.88%
Over 3 Years
162.55%
Aurobindo Pharma Ltd Summary
Close ₹1,223.10
Open ₹1,215.40
High ₹1,226.80
Low ₹1,209.10
Volume 7,40,597
Net Turnover (in Cr) ₹90.31
52Wk High ₹1,356.20
52Wk Low ₹1,010
52Wk High / Low
1,010
1,356.20
Aurobindo Pharma Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹71,037.85
EPS (TTM) 34.79
Book Value (BV) 369.16
Div. Yield -
P/E (TTM) 35.17
Price/Book Value 3.31
Delivery % 50.55 %
Face Value 1
Key Ratios
PE Ratio 38.55
PB Ratio 3.28
EV to Sales 6.61
PEG Ratio -3.93
ROA 6.92
ROE 8.68
Debt-Equity 0.19
Net Profit Margin 15.98
Operating Profit Margin 26.39
Aurobindo Pharma Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 32,345.58 | 29,559.25 | 25,145.97 | 23,775.84 | 25,155.47 |
| Total Expenses | 27,247.60 | 24,970.24 | 22,521.80 | 20,243.88 | 20,571.10 |
| Profit Before Tax | 5,066.29 | 4,379.99 | 2,612.50 | 3,372.74 | 7,343.59 |
| Profit After Tax | 3,483.57 | 3,168.97 | 1,927.65 | 2,647.11 | 5,333.82 |
| Operating Profit After Depreciation | 5,555.22 | 4,878.72 | 2,764.65 | 3,580.60 | 4,658.86 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 16,428.15 | 15,622.12 | 11,917.30 | 11,341.73 | 10,006.22 |
| Total Non Current Assets | 22,622.51 | 21,299.59 | 18,430.08 | 15,799.03 | 14,030.48 |
| Total Current Assets | 27,162.46 | 23,771.92 | 21,459.91 | 18,122.69 | 19,823.51 |
| Total Assets | 49,784.97 | 45,071.51 | 39,889.99 | 33,921.72 | 33,853.99 |
| Total Shareholder's Fund | 32,653.32 | 29,842.80 | 26,839.85 | 24,575.98 | 21,929.87 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 3,924.62 | 2,434.52 | 2,386.75 | 5,016.48 | 3,329.05 |
| Net Cash Used In Investing Activities | -1,866.04 | -4,241.78 | -3,971.40 | -3,211.36 | 596.57 |
| Net Cash Used In Financing Activities | 119.78 | 800.42 | 1,814.41 | -2,969.27 | -1,364.94 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 11,261.42 | 11,261.70 | 13,226.04 | 11,958.13 | 16,413.54 |
| Total Expenses | 8,902.97 | 8,858.78 | 11,611.69 | 10,245.94 | 12,220.53 |
| Profit Before Tax | 2,358.45 | 2,402.92 | 1,614.35 | 1,637.48 | 4,193.01 |
| Profit After Tax | 1,746.79 | 1,900.10 | 1,230.41 | 1,454.71 | 3,112.91 |
| Operating Profit After Depreciation | 2,588.49 | 2,585.52 | 1,729.33 | 1,729.13 | 4,221.69 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 2,336.80 | 2,419.13 | 3,687.50 | 3,585.83 | 4,487.94 |
| Total Non Current Assets | 19,823.66 | 17,914.85 | 15,210.01 | 11,765.84 | 10,811.13 |
| Total Current Assets | 7,689.40 | 7,239.13 | 9,723.64 | 9,835.11 | 12,377.86 |
| Total Assets | 27,513.06 | 25,153.98 | 24,933.65 | 21,600.95 | 23,188.99 |
| Total Shareholder's Fund | 20,534.11 | 19,722.82 | 17,914.17 | 17,117.34 | 15,924.61 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,645.79 | 1,714.80 | 1,821.16 | 3,726.71 | 2,994.41 |
| Net Cash Used In Investing Activities | -2,050.16 | -151.58 | -3,459.20 | -1,614.54 | -2,650.24 |
| Net Cash Used In Financing Activities | 616.31 | -1,837.03 | 1,719.48 | -2,447.54 | -27.94 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 8,285.70 | 7,868.14 | 8,382.12 | 7,978.52 | 7,796.07 |
| Total Expenses | 6,607.60 | 6,265.11 | 6,622.39 | 6,400.54 | 6,229.93 |
| Profit Before Tax | 1,275.92 | 1,206.80 | 1,335.09 | 1,199.85 | 1,207.46 |
| Profit After Tax | 848.13 | 824.20 | 902.83 | 845.57 | 816.95 |
| Operating Profit after Depreciation | 1,800.35 | 1,710.25 | 1,894.54 | 1,736.86 | 1,702.44 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 2,789.72 | 2,848.17 | 2,731.99 | 2,916.63 | 2,824.59 |
| Total Expenses | 2,065.02 | 2,051.83 | 2,135.48 | 2,203.48 | 2,103.71 |
| Profit Before Tax | 755.28 | 750.09 | 555.52 | 632.94 | 723.75 |
| Profit After Tax | 581.37 | 559.13 | 408.17 | 472.05 | 537.53 |
| Operating Profit after Depreciation | 884.22 | 880.11 | 710.49 | 767.41 | 843.54 |
Aurobindo Pharma Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 1,212.53
S2 1,201.97
S3 1,194.83
Pivot 1,219.67
R1 1,230.23
R2 1,237.37
R3 1,247.93
Moving Average
20 SMA 1,207.20
50 SMA 1,146.99
100 SMA 1,117.32
200 SMA 1,134.71
Aurobindo Pharma Ltd Corporate Actions
Aurobindo Pharma Ltd
₹4.0/Share
Announcement Date 08 Aug 2025
Record Date 08 Aug 2025
Div Yield 400%
Aurobindo Pharma Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,818.60 | ₹4,36,343.06 |
| Divis Laboratories Ltd | ₹6,470.60 | ₹1,71,774.10 |
| Torrent Pharmaceuticals Ltd | ₹3,801.65 | ₹1,28,659.33 |
| Cipla Ltd | ₹1,521.20 | ₹1,22,878.16 |
| Dr Reddys Laboratories Ltd | ₹1,277 | ₹1,06,581.13 |
Aurobindo Pharma Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Quant Mid Cap Fund | 7.97% |
| ICICI Pru P.H.D Fund | 7.62% |
| Quant Multi Cap Fund | 5.25% |
| Quant Flexi Cap Fund | 5.01% |
| Quant ELSS Tax Saver Fund | 4.74% |
Aurobindo Pharma Ltd News
Aurobindo Pharma Ltd soars 0.71%, gains for fifth straight session
Aurobindo Pharma Ltd is quoting at Rs 1218.8, up 0.71% on the day as on 12:44 IST on the NSE. The stock is down 1.34% in last one year as compared to a 10.05% jump in NIFTY and a 5.69% jump in the Nifty Pharma.
14 Nov 2025, 01:00 pm
USFDA issues EIR for Unit 1 of Apitoria Pharma
14 Nov 2025, 12:04 pm
Aurobindo Pharma Ltd soars 1.15%
Aurobindo Pharma Ltd is quoting at Rs 1112, up 1.15% on the day as on 12:49 IST on the NSE. The stock is down 20.86% in last one year as compared to a 7.15% spurt in NIFTY and a 0.31% spurt in the Nifty Pharma index.
29 Oct 2025, 01:05 pm
Aurobindo Pharma announces board meeting date
On 5 November 2025
25 Oct 2025, 11:05 am
Aurobindo Pharma gains after arm incorporates new subsidiary in Chile
Aurobindo Pharma rose 1.14% to Rs 1,113.55 after the company's wholly owned step-down subsidiary, Eugia Pharma B.V., incorporated a new wholly owned subsidiary in Chile, named Eugia Pharma Chile SpA.
23 Oct 2025, 11:57 am
Aurobindo Pharma Ltd Stock Analysis
- Annual revenue for Aurobindo Pharma Ltd remains unchanged by 0.00% to ₹11,261.42 crore in FY 2025 from ₹11,261.70 crore in FY 2024.
- Annual Net Profit for Aurobindo Pharma Ltd decreased by 8.07% to ₹1,746.79 crore in FY 2025 from ₹1,900.10 crore in FY 2024.
- Promoter Shareholding in Aurobindo Pharma Ltd remains unchanged by 0.00% in the most recent quarter, from 51.82% in June 2025 to 51.82% in September 2025.
- Aurobindo Pharma Ltd delivered a 1-year return of -2.88% compared to the Nifty 50, which provided a return of 6.40% as of the last trading session.
- Aurobindo Pharma Ltd share price moved down by 0.07% from its previous close of INR ₹1,223.10. The latest Aurobindo Pharma Ltd share price is INR ₹1,222.30.
- Aurobindo Pharma Ltd share price today has been at a low of 1,215.10 and a high of 1,226.40. Over the past 52 weeks, the Aurobindo Pharma Ltd share price has seen a low of 1,010 and a high of 1,356.20.
About Aurobindo Pharma Ltd
Aurobindo Pharma Limited is a major Indian pharmaceutical company. It has established itself as a key player in the global healthcare industry since its inception in 1986. The company's headquarters are in HITEC City in Hyderabad.
Aurobindo Pharma was founded by P.V. Ramprasad Reddy and K. Nityananda Reddy, who remain the primary promoters. The company’s extensive product portfolio includes antibiotics, antiretrovirals, cardiovascular products and anti-diabetics. Aurobindo Pharma has established a strong global presence, with its products being sold in over 150 countries. This international reach has positioned the company as one of India's largest pharmaceutical firms.
It is not currently the top-ranked stock in its sector. However, Aurobindo Pharma is a significant force in the generic pharmaceuticals market. The company’s registered office is located in Maitri Vihar, Ameerpet, Hyderabad. Meanwhile, the registrar’s office is in the Financial District. The company is led by Managing Director K Nithyananda Reddy. Apart from him, there are a lot of managerial promoters who have contributed to the success of the company. They are M Madan Mohan Reddy, Satakarni Makkapati, Girish P Vanvari, Santanu Mukherjee and Deepali Pant Joshi.
The Reddy family maintains a substantial promoter shareholding in the company, providing strong backing for its operations. Aurobindo Pharma’s success can be attributed to its experience and commitment to quality. As a result, Aurobindo Pharma continues to play a crucial role in providing accessible healthcare solutions worldwide. Its diverse range of products and strong market presence underscore its importance in the global pharmaceutical landscape.
One of Aurobindo Pharma’s key strategies is the rapid introduction of generic versions of drugs as soon as patents expire. This “Day-1 generic policy” ensures that patients have access to affordable alternatives without delay. Aurobindo Pharma helps lower the overall cost of medications. This is crucial for patients in low and middle-income countries.
Aurobindo Pharma also works on expanding its product portfolio to include a wide range of therapeutic areas. The company manufactures antibiotics and central nervous system medications, among others. This ensures that patients have access to treatments for different health conditions.
In addition to its product range, Aurobindo Pharma is committed to maintaining high standards of quality and safety. The company adheres to stringent regulatory requirements. It has also received approvals from major health authorities, including the US FDA and the European Medicines Agency. This commitment to quality ensures that patients receive safe and effective medications.
Aurobindo Pharma’s efforts extend beyond just manufacturing and distributing medicines. The company is also involved in initiatives to improve healthcare infrastructure and education. For example, Aurobindo Pharma collaborates with various organisations to support healthcare programs. These initiatives help strengthen the overall healthcare system and improve patient outcomes.
Moreover, Aurobindo Pharma is actively working to address the issue of antimicrobial resistance (AMR). The company has implemented measures to ensure responsible manufacturing practices. This has reduced the environmental impact of antibiotic production. As a result, Aurobindo Pharma contributes to global efforts to combat AMR.
Aurobindo Pharma’s commitment to accessibility is also evident in its efforts to reach underserved markets. The company has expanded its presence in Africa and Asia, where access to affordable medicines is often limited. It has increased the availability of its products in these regions. As a result, Aurobindo Pharma helps bridge the gap in healthcare access and improve the quality of life for many patients.
Aurobindo Pharma’s approach to reshaping access to medicine is multifaceted. The company not only focuses on affordability but also on ensuring the quality and safety of its products. This dual focus is essential in providing reliable healthcare solutions to patients worldwide. Aurobindo Pharma collaborates with various organisations, including non-profits and the government. This is to enhance its impact on global health. These partnerships enable the company to participate in large-scale health initiatives. Aurobindo Pharma also works together with other stakeholders. This allows the company to leverage their expertise and resources to achieve broader health outcomes.
Looking ahead, Aurobindo Pharma aims to continue expanding its global footprint. The company plans to enter new markets and introduce innovative treatments. With a strong focus on affordability, Aurobindo Pharma is well-positioned to make a lasting impact on global health. Aurobindo Pharma actively engages with the communities where it operates. The company supports various social initiatives, including education and infrastructure development. As a result, it contributes to the overall well-being of society.
Aurobindo Pharma’s approach to reshaping access to medicine encompasses affordability and quality. It also focuses on sustainability and education. The company’s initiatives are making a major impact on global health, ensuring that more people have access to the medicines they need. Through its continued efforts, Aurobindo Pharma is helping to create a healthier, more equitable world.
Aurobindo Pharma was founded by P.V. Ramprasad Reddy and K. Nityananda Reddy, who remain the primary promoters. The company’s extensive product portfolio includes antibiotics, antiretrovirals, cardiovascular products and anti-diabetics. Aurobindo Pharma has established a strong global presence, with its products being sold in over 150 countries. This international reach has positioned the company as one of India's largest pharmaceutical firms.
It is not currently the top-ranked stock in its sector. However, Aurobindo Pharma is a significant force in the generic pharmaceuticals market. The company’s registered office is located in Maitri Vihar, Ameerpet, Hyderabad. Meanwhile, the registrar’s office is in the Financial District. The company is led by Managing Director K Nithyananda Reddy. Apart from him, there are a lot of managerial promoters who have contributed to the success of the company. They are M Madan Mohan Reddy, Satakarni Makkapati, Girish P Vanvari, Santanu Mukherjee and Deepali Pant Joshi.
The Reddy family maintains a substantial promoter shareholding in the company, providing strong backing for its operations. Aurobindo Pharma’s success can be attributed to its experience and commitment to quality. As a result, Aurobindo Pharma continues to play a crucial role in providing accessible healthcare solutions worldwide. Its diverse range of products and strong market presence underscore its importance in the global pharmaceutical landscape.
How Aurobindo Pharma Is Reshaping Access to Medicine
Aurobindo Pharma is making significant contributions to improving access to medicine. The company focuses on producing affordable generic medicines, which helps reduce healthcare costs. This makes essential drugs more accessible to a broader population.One of Aurobindo Pharma’s key strategies is the rapid introduction of generic versions of drugs as soon as patents expire. This “Day-1 generic policy” ensures that patients have access to affordable alternatives without delay. Aurobindo Pharma helps lower the overall cost of medications. This is crucial for patients in low and middle-income countries.
Aurobindo Pharma also works on expanding its product portfolio to include a wide range of therapeutic areas. The company manufactures antibiotics and central nervous system medications, among others. This ensures that patients have access to treatments for different health conditions.
In addition to its product range, Aurobindo Pharma is committed to maintaining high standards of quality and safety. The company adheres to stringent regulatory requirements. It has also received approvals from major health authorities, including the US FDA and the European Medicines Agency. This commitment to quality ensures that patients receive safe and effective medications.
Aurobindo Pharma’s efforts extend beyond just manufacturing and distributing medicines. The company is also involved in initiatives to improve healthcare infrastructure and education. For example, Aurobindo Pharma collaborates with various organisations to support healthcare programs. These initiatives help strengthen the overall healthcare system and improve patient outcomes.
Moreover, Aurobindo Pharma is actively working to address the issue of antimicrobial resistance (AMR). The company has implemented measures to ensure responsible manufacturing practices. This has reduced the environmental impact of antibiotic production. As a result, Aurobindo Pharma contributes to global efforts to combat AMR.
Aurobindo Pharma’s commitment to accessibility is also evident in its efforts to reach underserved markets. The company has expanded its presence in Africa and Asia, where access to affordable medicines is often limited. It has increased the availability of its products in these regions. As a result, Aurobindo Pharma helps bridge the gap in healthcare access and improve the quality of life for many patients.
Aurobindo Pharma’s approach to reshaping access to medicine is multifaceted. The company not only focuses on affordability but also on ensuring the quality and safety of its products. This dual focus is essential in providing reliable healthcare solutions to patients worldwide. Aurobindo Pharma collaborates with various organisations, including non-profits and the government. This is to enhance its impact on global health. These partnerships enable the company to participate in large-scale health initiatives. Aurobindo Pharma also works together with other stakeholders. This allows the company to leverage their expertise and resources to achieve broader health outcomes.
Looking ahead, Aurobindo Pharma aims to continue expanding its global footprint. The company plans to enter new markets and introduce innovative treatments. With a strong focus on affordability, Aurobindo Pharma is well-positioned to make a lasting impact on global health. Aurobindo Pharma actively engages with the communities where it operates. The company supports various social initiatives, including education and infrastructure development. As a result, it contributes to the overall well-being of society.
Aurobindo Pharma’s approach to reshaping access to medicine encompasses affordability and quality. It also focuses on sustainability and education. The company’s initiatives are making a major impact on global health, ensuring that more people have access to the medicines they need. Through its continued efforts, Aurobindo Pharma is helping to create a healthier, more equitable world.
FAQ’s
What is the share price of Aurobindo Pharma Ltd today?
Aurobindo Pharma Ltd share price as on 5 Dec 2025 is ₹ 1222.3
What is the Market Cap of Aurobindo Pharma Ltd?
The market cap of Aurobindo Pharma Ltd stock is ₹71,037.85 Cr.
What is the PE Ratio of Aurobindo Pharma Ltd?
The Price to Earnings (P/E) Ratio of Aurobindo Pharma Ltd is 38.55
What is the PB Ratio of Aurobindo Pharma Ltd?
The Price to Book (P/B) Ratio of Aurobindo Pharma Ltd is 3.28
What is the 52 week high of Aurobindo Pharma Ltd Share Price?
The 52 week high of Aurobindo Pharma Ltd share price stands at ₹1,356.20
What is the 52 week low of Aurobindo Pharma Ltd Share Price?
The 52 week low of Aurobindo Pharma Ltd share price stands at ₹1,010
How can I buy shares of Aurobindo Pharma Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Aurobindo Pharma Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
